Search results
28 cze 2024 · Patients treated with IST need life-long monitoring by BM biopsies with cytogenetics and NGS to allow timely intervention with allogeneic HCT for MN. Even so, allogeneic HCT for monosomy 7 AML, for example, provides a 2-year leukemia-free survival of only 28.5% and a 2-year OS of 34.9% [ 18 ].
5 sty 2022 · Aplastic anemia is the prototype of the bone marrow failure syndromes that are characterized by hypocellular marrow and pancytopenia, and severe aplastic anemia is fatal if untreated. 1...
1 kwi 2019 · Although a rare disease, aplastic anemia should be distinguished from other cases of pancytopenia, and patients should receive the best treatment available based on their age, and the existence of a matched sibling donor.
6 sty 2022 · Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant (BMT) or immunosuppression (IST) depending on their age, comorbidities, and available donors.
5 kwi 2024 · The key diagnostic challenge is to identify the underlying condition involved in aplasia in individual patients to choose the optimal treatment option: either allogeneic hematopoietic cell transplantation (alloHCT) or immunosuppressive therapy (IST).
1 sie 2024 · For patients aged <40 years, the estimated OS after 3 years was 94.6 ± 2.7% in the IST + EPAG group and 82.9 ± 3.4% in the Haplo-HSCT group (P = 0.013) (Fig. 2c). The estimated FFS after 3...
In the IST + EPAG and Haplo-HSCT, 3-year overall survival (OS) was 92.4 ± 2.4% and 82.8 ± 3.1% (P = 0.017), whereas 3-year failure-free survival (FFS) was 69.4 ± 4.2% and 81.6 ± 3.2% (P = 0.002), respectively. Similar results were observed in patients with <40 years of age.
